These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 24065477)

  • 21. Hepatic arterial infusion of oxaliplatin, 5-fluorouracil and leucovorin in patients with liver metastases from colorectal carcinoma.
    Melichar B; Ferko A; Krajina A; Rousková L; Dvorák J; Svébisova H; Neoral C; Köcher M; Malirová E; Paral J
    J BUON; 2012; 17(4):677-83. PubMed ID: 23335524
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure.
    Boige V; Malka D; Elias D; Castaing M; De Baere T; Goere D; Dromain C; Pocard M; Ducreux M
    Ann Surg Oncol; 2008 Jan; 15(1):219-26. PubMed ID: 17896145
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Addition of Bevacizumab to First-Line Chemotherapy for Metastatic Colorectal Cancer.
    Tsutsumi S; Fujii T; Yamaguchi S; Suto T; Yajima R; Morita H; Kato T; Asao T; Kuwano H
    Hepatogastroenterology; 2014 May; 61(131):633-7. PubMed ID: 26176048
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Perioperative chemotherapy with or without bevacizumab in patients with metastatic colorectal cancer undergoing liver resection.
    Constantinidou A; Cunningham D; Shurmahi F; Asghar U; Barbachano Y; Khan A; Mudan S; Rao S; Chau I
    Clin Colorectal Cancer; 2013 Mar; 12(1):15-22. PubMed ID: 23021126
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hepatic arterial infusion of oxaliplatin and L-folinic acid-modulated 5-fluorouracil for colorectal cancer liver metastases.
    Neyns B; Van Nieuwenhove Y; Aerts M; Fontaine C; Vermeij J; Schallier D; Decoster L; De Mey J; Vandenbroucke F; Hoorens A; Delvaux G; De Gréve J
    Anticancer Res; 2006; 26(1B):611-9. PubMed ID: 16739329
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II).
    Hoff PM; Hochhaus A; Pestalozzi BC; Tebbutt NC; Li J; Kim TW; Koynov KD; Kurteva G; Pintér T; Cheng Y; van Eyll B; Pike L; Fielding A; Robertson JD; Saunders MP
    J Clin Oncol; 2012 Oct; 30(29):3596-603. PubMed ID: 22965965
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Retrospective study as first-line chemotherapy combined anti-VEGF antibody with fluoropyrimidine for frail patients with unresectable or metastatic colorectal cancer.
    Yoshida M; Goto M; Kii T; Nishitani H; Kawabe S; Kuwakado S; Asaishi K; Miyamoto T; Higuchi K
    Digestion; 2013; 87(1):59-64. PubMed ID: 23343971
    [TBL] [Abstract][Full Text] [Related]  

  • 28. S-1 and irinotecan with or without bevacizumab versus 5-fluorouracil and leucovorin plus oxaliplatin with or without bevacizumab in metastatic colorectal cancer: a pooled analysis of four phase II studies.
    Iwasa S; Nagashima K; Yamaguchi T; Matsumoto H; Ichikawa Y; Goto A; Yasui H; Kato K; Okita NT; Shimada Y; Yamada Y
    Cancer Chemother Pharmacol; 2015 Sep; 76(3):605-14. PubMed ID: 26220845
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hepatic arterial infusion chemotherapy using fluorouracil followed by systemic therapy using oxaliplatin plus fluorouracil and leucovorin for patients with unresectable liver metastases from colorectal cancer.
    Seki H; Ozaki T; Shiina M
    Cardiovasc Intervent Radiol; 2009 Jul; 32(4):679-86. PubMed ID: 19296157
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis.
    Martin RC; Scoggins CR; Schreeder M; Rilling WS; Laing CJ; Tatum CM; Kelly LR; Garcia-Monaco RD; Sharma VR; Crocenzi TS; Strasberg SM
    Cancer; 2015 Oct; 121(20):3649-58. PubMed ID: 26149602
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FOLFIRINOX bevacizumab is a promising therapy for chemorefractory metastatic colorectal cancer.
    Chaix M; Vincent J; Lorgis V; Ghiringhelli F
    Oncology; 2014; 87(3):148-58. PubMed ID: 25012455
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Conversion chemotherapy using cetuximab plus FOLFIRI followed by bevacizumab plus mFOLFOX6 in patients with unresectable liver metastases from colorectal cancer.
    Uehara K; Ishiguro S; Hiramatsu K; Nishio H; Takeuchi E; Takahari D; Yoshioka Y; Takahashi Y; Ebata T; Yoshimura K; Muro K; Nagino M
    Jpn J Clin Oncol; 2011 Oct; 41(10):1229-32. PubMed ID: 21840871
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group.
    Porschen R; Arkenau HT; Kubicka S; Greil R; Seufferlein T; Freier W; Kretzschmar A; Graeven U; Grothey A; Hinke A; Schmiegel W; Schmoll HJ;
    J Clin Oncol; 2007 Sep; 25(27):4217-23. PubMed ID: 17548840
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oxaliplatin with weekly bolus fluorouracil and low-dose leucovorin as first-line therapy for patients with colorectal cancer.
    Hochster H; Chachoua A; Speyer J; Escalon J; Zeleniuch-Jacquotte A; Muggia F
    J Clin Oncol; 2003 Jul; 21(14):2703-7. PubMed ID: 12860947
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of oxaliplatin-based chemotherapy in curatively resected colorectal cancer with liver metastasis.
    Kim HR; Min BS; Kim JS; Shin SJ; Ahn JB; Rho JK; Kim NK; Rha SY
    Oncology; 2011; 81(3-4):175-83. PubMed ID: 22057187
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment rationale and study design for a randomized, double-blind, placebo-controlled phase II study evaluating onartuzumab (MetMAb) in combination with bevacizumab plus mFOLFOX-6 in patients with previously untreated metastatic colorectal cancer.
    Bendell JC; Ervin TJ; Gallinson D; Singh J; Wallace JA; Saleh MN; Vallone M; Phan SC; Hack SP
    Clin Colorectal Cancer; 2013 Sep; 12(3):218-22. PubMed ID: 23810377
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III).
    Schmoll HJ; Cunningham D; Sobrero A; Karapetis CS; Rougier P; Koski SL; Kocakova I; Bondarenko I; Bodoky G; Mainwaring P; Salazar R; Barker P; Mookerjee B; Robertson J; Van Cutsem E
    J Clin Oncol; 2012 Oct; 30(29):3588-95. PubMed ID: 22965961
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and effectiveness of oxaliplatin-based chemotherapy regimens in adults 75 years and older with colorectal cancer.
    McCleary NJ; Odejide O; Szymonifka J; Ryan D; Hezel A; Meyerhardt JA
    Clin Colorectal Cancer; 2013 Mar; 12(1):62-9. PubMed ID: 23102897
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer.
    Tabernero J; Van Cutsem E; Díaz-Rubio E; Cervantes A; Humblet Y; André T; Van Laethem JL; Soulié P; Casado E; Verslype C; Valera JS; Tortora G; Ciardiello F; Kisker O; de Gramont A
    J Clin Oncol; 2007 Nov; 25(33):5225-32. PubMed ID: 18024868
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Selective Internal Radiation Therapy (SIRT) with yttrium-90 resin microspheres plus standard systemic chemotherapy regimen of FOLFOX versus FOLFOX alone as first-line treatment of non-resectable liver metastases from colorectal cancer: the SIRFLOX study.
    Gibbs P; Gebski V; Van Buskirk M; Thurston K; Cade DN; Van Hazel GA;
    BMC Cancer; 2014 Dec; 14():897. PubMed ID: 25487708
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.